Previous 10 | Next 10 |
Gainers: Sonoma Pharmaceuticals (SNOA) +29%. Blue Water Vaccines (BWV) +32%. XORTX Therapeutics (XRTX) +27%. Eqonex (EQOS) +21%. TETRA Technologies (TTI) +20%. Enovix (ENVX) +18%. JAKKS Pacific (JAKK) +18%. Blue Apron Holdings (APRN) +17%. Borr Drilling (BORR) +16%. Western Digital Corp...
Gainers: Sonoma Pharmaceuticals (SNOA) +42%. XORTX Therapeutics (XRTX) +18%. Retractable Technologies (RVP) +14%. Catalent (CTLT) +12%. Field Trip Health (FTRP) +5%. Losers: Spero Therapeutics (SPRO) -61%. Semler Scientific (SMLR) -23%. Galmed Pharmaceu...
CALGARY, Alberta, May 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce t...
CALGARY, Alberta, April 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...
CALGARY, Alberta, April 12, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...
CALGARY, Alberta, April 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...
XORTX Therapeutics (OTCQB:XRTXF) filed an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow a clinical study of XRx-008 to treat progressing kidney disease due to autosomal dominant polycystic kidney disease (ADPKD). The IND contains the protocol f...
● Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program IND Filed ● CALGARY, Alberta, March 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX I TSXV: XRTX I Frankfurt: ANU), a pharmaceutical ...
Gainers: Creative Medical Technology Holdings CELZ +74%. 4D pharma LBPS +26%. XORTX Therapeutics (XRTX) +26%. Clear Secure YOU +24%. Alpha Tau Medical (DRTS) +21%. Waterdrop WDH +21%. Cenntro Electric Group CENN +20%. Femasys FEMY +20%. Q&K International Grou...
CALGARY, Alberta, March 23, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney diseas...
News, Short Squeeze, Breakout and More Instantly...
XORTX Therapeutics Inc. Company Name:
XRTX Stock Symbol:
NASDAQ Market:
XORTX Therapeutics Inc. Website:
CALGARY, June 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to anno...
CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive ...